A clinical study of Yigu capsule in treating postmenopausal osteoporosis

被引:6
作者
Zhang Rong-hua
Chen Ke-ji
Lu Da-xiang
Zhu Xiao-feng
Ma Xiao-chang
机构
[1] The First Affiliated Hospital of Jinan University,Xiyuan Hospital
[2] China Academy of Traditional Chinese Medicine,undefined
关键词
postmenopausal osteoporosis; treatment; Yigu capsule;
D O I
10.1007/BF02836464
中图分类号
学科分类号
摘要
Objective: To observe the efficacy and safety of Yigu capsule (YGC), a Chinese herbal compound preparation, in treating postmenopausal osteoporosis (PMO) and to explore its possible mechanism.Methods: The clinical study was conducted in a prospective, randomized, double blinded method lasting for 6 months with placebo and positive control. Two hundred and ten PMO patients with confirmed diagnosis were assigned into the YGC group, the calciferol group and the placebo group. Besides being administered element calcium, they were treated with YGC, calciferol capsule and placebo capsule respectively. And such symptoms as newly found fracture and ostealgia, bone mineral density (BMD) of the 2nd–4th lumbar vertebrae (L2–4) and upper femur, blood and urinary indexes for bone metabolism, sex hormone level and adverse reaction that occurred in patients were observed.Results: In the YGC group, the total effective rate was 95. 50%, with no new occurrence of fractures, which was significantly better than that in the other two groups (P<0.05). Moreover, in the YGC group, the increase rate of BMD was 9.83% in L2–4, 4.09% in femoral neck, 4.60% in Wards triangle, 3.00% in greater trochanter, which was also better than that in the placebo group (P<0.05,P<0.01). As compared with the placebo group, levels in the YGC group of urinary oxyproline hydroxyproline/creatinine, urinary calcium/creatinine were significantly lower, serum and bone alkaline phosphatase, osteocalcin, estradiol and estradiol/testosterone were significantly higher, but no difference was shown in the comparison of testosterone level. In the observation period, no abnormality in blood or urine routine, liver or renal function was found. Only mild, transient gastro-intestinal response occurred in individual patients, but it did not affect the treatment.Conclusion: YGC could treat PMO effectively, as it could obviously increase the BMD of lumbar vertebrae and coxafemoral bone, elevate the alleviating rate of ostealgia and incessant motion time, yet causing no newly found compressive fracture of vertebrae, or and any related adverse reaction. YGC could not only promote the formation, but also inhibit the absorption of bone as well as increase the sex hormone level. Therefore, it is a pure Chinese herbal compound preparation worthy of further research and development.
引用
收藏
页码:97 / 103
页数:6
相关论文
共 13 条
[1]
Nelson HD(2002)Postmenopausal hormone replacement therapy: scientific review JAMA 288 872-881
[2]
Humphrey LL(1999)Osteoporosis and its prevention and treatment J Jinan Univ (Medicine Edition) 20 32-37
[3]
Nygren P(1997)Apparent pre and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort J Bone Miner Res 12 683-690
[4]
Zhang RH(1997)A new trabecular region of interest for femoral dual X-ray absorption metry: short-term precision, age-related bone loss, and fracture discrimination compared with current femoral regions of interest J Bone Miner Res 12 832-838
[5]
Arlot ME(1999)Effect of Chinese recipes of replenishing Shen and activating blood circulation on female rats with osteoporosis induced by ovariectomy Chin J Integr Tradit West Med 19 614-616
[6]
Sornay-Rendu E(undefined)undefined undefined undefined undefined-undefined
[7]
Garnero P(undefined)undefined undefined undefined undefined-undefined
[8]
Takada M(undefined)undefined undefined undefined undefined-undefined
[9]
Grampp S(undefined)undefined undefined undefined undefined-undefined
[10]
Ouyang X(undefined)undefined undefined undefined undefined-undefined